Validation of ICD ‐10‐ CM Codes for Bleeding in Patients With an Indication for Antithrombotic Therapy
Pharmacoepidemiology and Drug Safety · 2026-11 · 35 (11)
DOI: 10.1002/pds.70531 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 13.11.2026. Verfasst von Sultan I Khan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Washington University in St. Louis, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: International Classification of Diseases, Fibrinolytic Agents, Hemorrhage. Die Arbeit nennt 32 Literaturangaben. Gefördert von: JG CDC HHS, Norman Knowlton Foundation and Fellowship, Centers for Disease Control and Prevention.
Abstract (Originalsprache)
Background
International Classification of Disease Clinical Modification (ICD‐10‐CM) codes are used to identify adverse drug events. Our goal was to assess accuracy of ICD‐10‐CM code assignments in billing data for identifying hospital encounters for overt bleeds.
Methods
Multicenter, case–control study of patients with indications for antithrombotic therapy and who had an emergency department or hospital admission. Cases identified by ICD‐10‐CM codes for bleeding were matched 2:1 to controls. Medical record abstraction was the reference standard for determining bleeding occurrence and anatomical location. Diagnostic accuracy of ICD‐10‐CM codes for bleeding overall was calculated while adjusting for oversampling of cases.
Results
Among 4803 patients (3140 cases, 1663 controls), ICD‐10‐CM codes for bleeds in any position had positive predictive value (PPV) of 88.5% (95% CI, 87.4%–89.7%) and adjusted sensitivity of 75.2% (70.9%–79.4%). Intracranial bleed codes had the highest PPV (93.1%; 95% CI, 91.3%–94.9%) and adjusted sensitivity (100%; 95% CI, 94.0%–100.0%). Gastrointestinal bleed codes and codes for other bleeds had PPVs (95% CI) of 83.1% (81.2%–85.0%) and 77.2% (74.6%–79.8%) and adjusted sensitivities (95% CI) of 84.8% (78.5%–91.1%) and 52.2% (46.2%–58.8%), respectively. Restricting codes to the primary diagnosis position increased PPV of any bleed to 97.2% (96.5%–97.9%), but decreased adjusted sensitivity to 44.9% (40.79%–49.6%). Codes for antithrombotic poisoning/adverse effect had PPV of 88.4% (83.9%–93.0%) but adjusted sensitivity of 5.6% (5.3%–5.9%).
Conclusions
When using ICD‐10‐CM codes to identify overt bleeding in patients who have an indication for antithrombotic therapy, codes in the primary position have the highest PPV. Use of codes in any position maximizes sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Washington University in St. Louis, St. Louis, Missouri, USA.
- University of Nevada, Reno, Nevada, USA.
- Baylor University Medical Center, Dallas, Texas, USA.
- University of California, Davis, California, USA.
- Health Services Advisory Group, Inc., Phoenix, Arizona, USA.
- Mount Sinai Health System, New York, New York, USA.
ORCID-Profile: Sultan I Khan, Margaret A Olsen, Roger D Yusen, Richard White, Brian F Gage
Förderung
- JG CDC HHS
- Norman Knowlton Foundation and Fellowship
- Centers for Disease Control and Prevention
Zitieren
APA
Khan, S. I., Sharma, Y., Olsen, M. A., Yusen, R. D., White, R., Yang, T. H., Saeed, R., Atolagbe, O., Lin, H., & Gage, B. F. (2026). Validation of ICD ‐10‐ CM Codes for Bleeding in Patients With an Indication for Antithrombotic Therapy. Pharmacoepidemiology and Drug Safety, 35(11). https://doi.org/10.1002/pds.70531
Vancouver
Khan SI, Sharma Y, Olsen MA, Yusen RD, White R, Yang TH, et al. Validation of ICD ‐10‐ CM Codes for Bleeding in Patients With an Indication for Antithrombotic Therapy. Pharmacoepidemiology and Drug Safety. 2026;35(11). doi:10.1002/pds.70531
BibTeX
@article{Khan2026,
author = {Khan, Sultan I and Sharma, Yeshika and Olsen, Margaret A and Yusen, Roger D and White, Richard and Yang, Tsu-Hsuan and Saeed, Rabia and Atolagbe, Oluseun and Lin, Hannah and Gage, Brian F},
title = {Validation of ICD ‐10‐ CM Codes for Bleeding in Patients With an Indication for Antithrombotic Therapy},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
volume = {35},
number = {11},
doi = {10.1002/pds.70531}
}
EUVIMED